Home / Companies / Glenmark Pharmaceuticals Limited / 1 Aug 2025
Glenmark Pharmaceuticals Limited: meeting of 1 Aug 2025
Votes reported on Form N-PX, item by item
40 Form N-PX filers reported votes at the Glenmark Pharmaceuticals Limited meeting of 1 Aug 2025. Their records fall into 2 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
1 nominee; 100.0% of reported votes for; no filer withheld from or voted against at least one nominee.
4 vote records from 4 filers. 0 of the 4 filers that marked the item either way voted against management.
COMPENSATIONIssuer
COMPENSATION: management items
Management items in this category are shown together; filers word and number them differently.
55 vote records from 35 filers. 0 of the 35 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors |
|---|---|
| Charles Schwab | For |
| Hartford Funds | For |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Glenmark Pharmaceuticals Limited meeting?
40 Form N-PX filers reported votes at the meeting of 1 Aug 2025. The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Glenmark Pharmaceuticals Limited on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Glenmark Pharmaceuticals Limited
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Glenmark Pharmaceuticals Limited with a meeting date within three days of 1 Aug 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.